BioTuesdays

Category - Markets

Helius Medical Technologies Logo

Mackie cuts Helius Medical to hold

Mackie Research downgraded Helius Medical Technologies (TSX:HSM) to “hold” from “speculative buy,” but maintained its price target of $2.70 (Canadian). The stock closed at $3.50 on Sept. 19.

ProMIS Neurosciences

Mackie starts Promis at speculative buy

Mackie Research Capital initiated coverage of Promis Neurosciences (TSX:PMN) with a “speculative buy” rating and price target of 50 cents, saying the company has a promising new path to target Alzheimer’s disease (AD)...

Synlogic

Leerink starts Synlogic at OP

Leerink launched coverage of Synlogic (NASDAQ:SYBX) with an “outperform” rating and $25 price target. The stock closed at $18.73 on Sept. 18. Synlogic is a leader in the potentially revolutionary field of synthetic...

Arrowhead Pharmaceuticals

WB ups Arrowhead to OP

William Blair upgraded Arrowhead Pharmaceuticals (NASDAQ:ARWR) to “outperform” from “market perform” and raised its fair value estimate to $6 from $2 after the company’s R&D day on Sept. 14. The stock closed at $3...

Tactile Systems Technology

BTIG cuts Tactile Systems to neutral

BTIG downgraded Tactile Systems Technology (NASDAQ:TCMD) to “neutral” from “buy,” saying the stock is up more than 100% year-to-date, exceeding its price target of $35. The stock closed at $36.79 on Sept. 15. Tactile...

Applied Genetic

HCW cuts Applied Genetic price target to $8

H.C. Wainwright slashed its price target for Applied Genetic Technologies (NASDAQ:AGTC) to $8 from $16 but maintained its “buy” rating after the company posted financing results below consensus for the fiscal year ended...

Sientra Logo

WB ups Sientra to OP

William Blair upgraded Sientra (NASDAQ:SIEN) to “outperform” from “market perform,” saying the company’s corporate strategy should begin to pay off over the next six-to-18 months. Sientra is a medical aesthetics company...

Collegium Pharma

HCW starts Collegium at buy

H.C. Wainwright initiated coverage of Collegium Pharmaceuticals (NASDAQ:COLL) with a “buy” rating and $21 price target. The stock closed at $10.21 on Sept. 8. Collegium is a leading player in the abuse-deterrent...

NewLink Genetics

Stifel ups NewLink price target to $29

Stifel raised its price target for NewLink Genetics (NASDAQ:NLNK) to $29 from $14 after the company on the weekend updated Phase 2 data in patients with advanced melanoma. The stock closed at $17.67 on Sept. 8. In a...

NeoGenomics

BTIG cuts NeoGenomics to neutral

BTIG downgraded NeoGenomics (NASDAQ:NEO) to “neutral” from “buy,” citing hurricanes that have hit Texas and Florida and noting that the shares are near its $11 price target, almost reaching an all-time high. The stock...